{"id":"W4323033688","doi":"10.1016/s1470-2045(23)00052-9","title":"Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"Pfizer Canada; European Society for Medical Oncology; Merck Sharp and Dohme; Eisai; Bayer HealthCare; Seagen; Incyte; Ipsen; Clovis Oncology; PharmaMar; Ipsen Biopharmaceuticals; AstraZeneca Canada; Gilead Sciences; Mersana Therapeutics; Bristol-Myers Squibb; AstraZeneca; Takeda Oncology; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Bevacizumab; Pembrolizumab; Carboplatin; Chemotherapy; Placebo; Clinical endpoint; Internal medicine; Cervical cancer; Oncology; Cancer; Surgery; Clinical trial; Cisplatin; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001753772,0.002001444,0.003672155,0.0005570693,0.0005311499,0.001172869,0.0009997102,0.002264408,0.008738752],"category_scores_gemma":[0.001854542,0.0008032882,0.00261096,0.0004903137,0.001442789,0.001263305,0.0004918707,0.003816276,0.001338844],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009156744,"about_ca_system_score_gemma":0.0008880109,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001552845,"about_ca_topic_score_gemma":0.002727583,"domain_scores_codex":[0.9993204,0.0003254573,0.00003977918,0.000156418,0.00004591832,0.000112117],"domain_scores_gemma":[0.9993868,0.0002234404,0.0001452642,0.00004368763,0.00003678831,0.0001640235],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9866022,0.002265243,0.0001348422,0.0007735554,0.0006964133,0.00001572884,0.00002651774,0.0001438403,0.001230517,0.00006647957,0.0004160033,0.007628783],"study_design_scores_gemma":[0.9721947,0.02633532,0.0005120533,0.0000344356,0.0003061172,0.00001151154,0.00001013218,0.0001390041,0.0001354167,0.00007589987,0.0002379564,0.000007614801],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9715409,0.01395146,0.001046131,0.001084774,0.001457975,0.005328671,0.001618771,0.0002410565,0.003730159],"genre_scores_gemma":[0.9818747,0.004565287,0.001605801,0.001233034,0.0005440289,0.00524455,0.0009874087,0.00002861598,0.00391656],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008738752,"threshold_uncertainty_score":0.02923405,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2100095022740117,"score_gpt":0.4556659257109718,"score_spread":0.24565642343696,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}